H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Evommune (EVMN) with a Buy rating and $35 price target The firm says that following the recent pullback, Evommune shares offer a favorable risk/reward into the company’s 2026 readouts. The firm sees a lack of competition for MRGPRX2. Evommune’s repeat-builder management increases the likelihood that positive 2026 data translate into strategic interest, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- 3 ‘Strong Buy’ Stocks to Buy Now,12/30/2025, According to Top Analysts
- Evommune: Multiple 2026 Phase II Readouts and Novel Immunology Mechanisms Drive Compelling Buy-Rated Risk‑Reward
- Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential
- Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating
- Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%